Humana Inc. (NYSE:HUM) Shares Sold by Pitcairn Co.

Pitcairn Co. decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 16.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,033 shares of the insurance provider’s stock after selling 203 shares during the quarter. Pitcairn Co.’s holdings in Humana were worth $262,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Norges Bank acquired a new stake in Humana in the 4th quarter valued at approximately $416,202,000. Pzena Investment Management LLC raised its stake in Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. Boston Partners boosted its position in Humana by 435.8% during the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after acquiring an additional 893,637 shares during the period. Finally, Artisan Partners Limited Partnership grew its stake in shares of Humana by 83.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 673,715 shares of the insurance provider’s stock worth $170,928,000 after purchasing an additional 306,433 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of NYSE HUM opened at $253.37 on Monday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The business’s 50-day moving average price is $267.58 and its two-hundred day moving average price is $271.55. The company has a market capitalization of $30.58 billion, a P/E ratio of 25.46, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is presently 35.58%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Morgan Stanley decreased their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. JPMorgan Chase & Co. dropped their target price on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Finally, Truist Financial increased their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Eighteen analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $280.17.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.